📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Karius

1.1 - Company Overview

Karius Logo

Karius

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of genomic insights into infectious diseases via the Karius Test, a liquid biopsy detecting over 1,000 pathogens from a single blood sample for rapid, non-invasive diagnosis. Offers microbial cell-free DNA detection, AI-driven real-time analysis against proprietary reference genome databases, and clinical and analytical validation, helping clinicians make critical, life-saving treatment decisions.

Products and services

  • The Karius Test: A non-invasive, liquid-biopsy product that detects over 1,000 pathogens from a single blood sample, enabling rapid infectious disease diagnosis and supporting critical clinician decisions
  • AI Technology: A machine-learning–driven system that performs real-time analysis of complex genomic data against proprietary reference genome databases to interpret pathogen signals and support life-saving clinical decisions
  • Microbial Cell-Free DNA Detection: A cfDNA-based approach that identifies microbial cell-free DNA from over 1,000 pathogens circulating in the bloodstream, leveraging genomic insights to pinpoint infectious organisms.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Karius

Quick-Med Technologies Logo

Quick-Med Technologies

HQ: United States Website
  • Description: Provider of proprietary, broad-based life sciences technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Quick-Med Technologies company profile →
Lumora Logo

Lumora

HQ: United Kingdom Website
  • Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Lumora company profile →
Excelimmune Logo

Excelimmune

HQ: United States Website
  • Description: Provider of fully human recombinant polyclonal antibodies for therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Excelimmune company profile →
Spectral Medical Logo

Spectral Medical

HQ: Canada Website
  • Description: Provider of therapies and diagnostics for septic shock and sepsis risk, including Toraymyxin (PMX) hemoperfusion to remove endotoxin and the Endotoxin Activity Assay (EAA). Conducts the Tigris Phase 3 study of PMX with standard care. Also offers the DIMI hemodialysis system for continuous renal replacement therapy, licensed for hospitals, clinics, and homes in Canada and the USA, and the SAMI device for continuous renal replacement therapy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Spectral Medical company profile →
Acurx Pharmaceuticals Logo

Acurx Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage antibiotics for difficult-to-treat infections, including ibezapolstat, an antibiotic in Phase 2b for C. difficile infection showing promise in clinical cure and sustained clinical cure with potential microbiome benefits, and ACX-375C, a preclinical program developing systemic Gram-positive selective-spectrum antibiotics targeting multi-drug resistant and sensitive pathogens.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Acurx Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Karius

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Karius

2.2 - Growth funds investing in similar companies to Karius

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Karius

4.2 - Public trading comparable groups for Karius

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Karius

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Karius

What does Karius do?

Karius is a provider of genomic insights into infectious diseases via the Karius Test, a liquid biopsy detecting over 1,000 pathogens from a single blood sample for rapid, non-invasive diagnosis. Offers microbial cell-free DNA detection, AI-driven real-time analysis against proprietary reference genome databases, and clinical and analytical validation, helping clinicians make critical, life-saving treatment decisions.

Who are Karius's competitors?

Karius's competitors and similar companies include Quick-Med Technologies, Lumora, Excelimmune, Spectral Medical, and Acurx Pharmaceuticals.

Where is Karius headquartered?

Karius is headquartered in United States.

How many employees does Karius have?

Karius has 1,000 employees 🔒.

When was Karius founded?

Karius was founded in 2010 🔒.

What sector and industry vertical is Karius in?

Karius is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Karius

Who are the top strategic acquirers in Karius's sector and industry

Top strategic M&A buyers and acquirers in Karius's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Karius?

Top strategic M&A buyers groups and sectors for Karius include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Karius's sector and industry vertical

Which are the top PE firms investing in Karius's sector and industry vertical?

Top PE firms investing in Karius's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Karius's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Karius's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Karius's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Karius include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Karius's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Karius?

The key public trading comparables and valuation benchmarks for Karius include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Karius for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Karius with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Karius's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Karius with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Karius's' sector and industry vertical?

Access recent funding rounds and capital raises in Karius's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Karius